BioSpace News Archive

The French Blood Establishment (EFS) and Brenus Pharma announce their strategic partnership in the bioproduction of innovative therapy drugs (ITD), highlighting French expertise.

Vaporox, a Denver based medical device company, has received clearance from the US Food and Drug Administration for its next generation VHT-200 medical device system for healing chronic wounds, which are wounds that do not respond to conventional wound treatment, meeting a significant unmet medical need for millions of sufferers of diabetic foot ulcers.

Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN) today reported financial results for the fourth quarter and full year ended December 31, 2022 and corporate updates.

Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immuno-oncology company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2022 and provided a corporate update.

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2022 financial results and provided a business update.

NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’) today announced that the company will postpone the release of its full year financial results initially scheduled for Tuesday, March 28, 2023 at 4:15 p.m. EDT and conference call initially scheduled for Wednesday, March 29, 2023.

Danaher Corporation announced that it will webcast its quarterly earnings conference call for the first quarter 2023 on Tuesday, April 25, 2023 beginning at 8:00 a.m. ET and lasting approximately 1 hour.

Thermo Fisher Scientific Inc. and the University of California, San Francisco, will accelerate advanced cell therapies for difficult to treat conditions, including cancer, rare diseases, and other illnesses, from a newly opened cGMP manufacturing facility adjacent to UCSF Medical Center’s Mission Bay campus.

Monopar Therapeutics Inc. (Nasdaq: MNPR) today announced completion of a pre-specified interim analysis for its Validive Phase 2b/3 VOICE trial for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC).

Transcat, Inc., a leading provider of accredited calibration services, enterprise asset management services, and value-added distributor of professional grade handheld test, measurement and control instrumentation, announced that it has purchased all of the capital stock of privately-held TIC-MS, Inc., effective March 27, 2023.